Fig. 1
miR-29b-2-5p has a positive correlation with the prognosis of pancreatic cancer and independently predicted better survival. a The flowchart of patient selection and schematic design. b Statistical analysis of miR-29b-2-5p expression in good and poor prognosis group, nonparametric Mann–Whitney test. All the bars represent SE. c Statistical analysis of miR-29b-2-5p expression in normal and cancerous pancreatic tissues, nonparametric Mann–Whitney test. All the bars represent SE. d In miRNA array cohort, miR-29b-2-5p high expression associated with a median survival of 35.2 months versus low expression of 6.4 months (log rank x2 = 21.837, p = 0.02). e In miRNA validation cohort, patients with high or low miR-29b-2-5p expression associated with a median OS respectively time of 18.8 or 12.9 months. (log rank x2 = 9.296, p = 0.002). f The good prognosis group levels of miR-29b-2-5p in these 100 validation cohort is higher than poor prognosis group. (p < 0.001)